Markets:

Overview

News

Currencies

International

Treasuries

ResMed Inc. Common Stock (NY:RMD)

259.18 +5.99 (+2.37%)

Streaming Delayed Price Updated: 3:56 PM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Insulet Earnings: What To Look For From PODD

February 19, 2025

Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect.

Via StockStory

iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect

February 19, 2025

Medical technology company iRhythm Technologies (NASDAQ:IRTC) will be announcing earnings results tomorrow afternoon. Here’s what investors should know.

Via StockStory

DexCom (DXCM) To Report Earnings Tomorrow: Here Is What To Expect

February 12, 2025

Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings tomorrow after the bell. Here’s what investors should know.

Via StockStory

ResMed Getting Close To Elite Stock Group Entry ↗

February 11, 2025

ResMed also boasts a 93 Composite Rating. The best growth stocks often have a 90 or higher Composite as they begin their biggest runs.

Via Investor's Business Daily

Stock Of The Day: Different Ways To Profit From SoundHound ↗

February 04, 2025

Shares of SoundHound AI are trading within a range. Some traders will get involved if the stock breaks out or breaks down.

Via Benzinga

Topics Artificial Intelligence

ResMed Earnings Analysis: Q2 Recap ↗

January 30, 2025

Via Benzinga

What 5 Analyst Ratings Have To Say About ResMed ↗

January 10, 2025

Via Benzinga

Should you consider RESMED INC (NYSE:RMD) for quality investing? ↗

November 29, 2024

RESMED INC (NYSE:RMD) may be suited for quality investing, we'll explore why in this article.

Via Chartmill

Stock Of The Day: Trading The Range In ResMed ↗

February 03, 2025

If shares of ResMed (RMD) reach support, potential buyers may start to outbid each other. This could force the shares into an uptrend.

Via Benzinga

What You Missed On Friday ↗

February 02, 2025

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.

Via Talk Markets

Topics Stocks / Equities

What's going on in today's session: S&P500 movers ↗

January 31, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

ResMed (NYSE:RMD) Posts Better-Than-Expected Sales In Q4 But Stock Drops

January 31, 2025

Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its non-GAAP profit of $2.43 per share was 5.2% above...

Via StockStory

Why Quality-Oriented Investors Should Consider NYSE:RMD. ↗

November 07, 2024

Exploring RESMED INC (NYSE:RMD)'s quality characteristics.

Via Chartmill

In today's session, there are S&P500 stocks with remarkable trading volume. ↗

January 31, 2025

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Via Chartmill

Top S&P500 movers in Friday's session ↗

January 31, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday? ↗

January 31, 2025

Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings and positive macroeconomic data. The S&P 500 index stands...

Via Benzinga

Topics Stocks

Friday's session: gap up and gap down stock in the S&P500 index ↗

January 31, 2025

Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session.

Via Chartmill

ResMed: Digital Health Drives Q2 Growth ↗

January 30, 2025

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability.

Via The Motley Fool

ResMed, In A Buy Zone, Stays Flat After Handily Beating Earnings Views ↗

January 30, 2025

The company easily beat earnings expectations, while sales were narrowly above.

Via Investor's Business Daily

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025

January 30, 2025

From ResMed Inc.

Via GlobeNewswire

Reasonable Growth, Debt Levels, and a High ROIC Make RESMED INC (NYSE:RMD) Appealing to Quality Investors. ↗

January 28, 2025

A fundamental analysis of (NYSE:RMD): Why Quality-Oriented Investors Should Consider NYSE:RMD.

Via Chartmill

Wall Street Remains Flat, Microsoft Eyes Heaviest Drop Since Late 2022, Gold Sets Fresh Records: What's Driving Markets Thursday? ↗

January 30, 2025

Wall Street is struggling to find risk-on momentum, with major indexes stuck near the flatline at midday as investors assess the latest earnings reports from mega-cap tech stocks and...

Via Benzinga

This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

January 10, 2025

Via Benzinga

ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

January 09, 2025

From ResMed Inc.

Via GlobeNewswire

Earnings Scheduled For January 30, 2025 ↗

January 30, 2025

Via Benzinga

ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

January 06, 2025

From ResMed Inc.

Via GlobeNewswire

Top Stock Reports For UnitedHealth, Costco & IBM ↗

January 03, 2025

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc., Costco Wholesale Corp., and International Business Machines Corp., as well as a micro-cap...

Via Talk Markets

Topics Stocks / Equities

Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive? ↗

December 20, 2024

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

Via Investor's Business Daily

This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

December 13, 2024

Via Benzinga

ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year ↗

November 18, 2024

ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.